SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced further data from its Phase 2A clinical study of OPT-80, a potential treatment for Clostridium difficile infection, or CDI, have been accepted for presentation at the 9th Biennial Congress of the Anaerobe Society of the Americas, to be held in Long Beach, CA, June 25-27, 2008. Pam Sears, Ph.D., Senior Director of Biology at Optimer, will be presenting the additional analyses which describe the strain types and antibiotic susceptibilities of Clostridium difficile isolated from patients in the Phase 2A study. The poster presentation, titled “Typing and Susceptibility of Bacterial Isolates from the OPT-80 (PAR-101) Phase 2A Study for C. Difficile-Associated Diarrhea,” will be held on Thursday, June 26 at 3:15pm Pacific Time.
